StockNews.AI
EVGN
StockNews.AI
103 days

Evogene Schedules First Quarter 2025 Financial Results Release

1. Evogene will release Q1 2025 financial results on May 21, 2025. 2. Management will host a call to discuss these results at 9:00 AM ET. 3. Evogene focuses on life-science product discovery using AI and big data. 4. The company operates tech-engines for microbiome and ag-chemical innovations. 5. Evogene holds partnerships for product development and has four key subsidiaries.

Earnings
-0.88%Current Return
VS
+0.7%S&P 500
$1.1405/08 07:14 AM EDTEvent Start
$1.1305/09 02:07 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings call will provide crucial financial insights but not immediate market surprises, similar to previous quarters where minimal changes were observed until actual earnings were released.

How important is it?

Earnings results directly influence stock performance and investor sentiment, making this information pivotal for stock price movement.

Why Short Term?

Investors await quarterly results, impacting stock sentiment in the days following the announcement but historically leading to volatility only surrounding earnings release dates.

Related Companies

Zoom conference call scheduled for May 21, 2025, 9:00 AM ET , /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a few days after. About Evogene: Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including: Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI; Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI. For more information, please visit: www.evogene.com. Contact [email protected] Tel: +972-8-9311901 Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg SOURCE Evogene WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News